三(二甲基氨基)(3H-1,2,3-三唑[4,5-b]吡啶-3-基氧代)膦六氟磷酸盐 | 156311-85-2

• 物质功能分类: 生物化工 - 缩合剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并吡啶类
• 中文名称: 三(二甲基氨基)(3H-1,2,3-三唑[4,5-b]吡啶-3-基氧代)膦六氟磷酸盐
• 中文别名: 7-氮杂苯并三唑-1-基氧基三(二甲胺基)膦六氟磷酸盐；7-氮杂-1H-苯并三唑-1-氧基三(二甲氨基)六氟磷酸磷；7-氮杂苯并三唑-1-基氧基三(二甲氨基)鏻六氟磷酸盐；六氟磷酸7-氮杂苯并三唑-1-氧基三(二甲氨基)磷；(7-氮杂苯并三唑-1-基氧代)三(三甲基氨基)膦六氟磷酸盐；AOP
• 英文名称: 7-Azabenzotriazol-1-Yloxytris(Dimethylamino)Phosphonium Hexafluorophosphate
• 英文别名: tris(dimethylamino)-(triazolo[4,5-b]pyridin-3-yloxy)phosphanium;hexafluorophosphate
• CAS: 156311-85-2
• 化学式: C11H21F6N7OP2
• 分子量: 443.27
• InChiKey: RQBNNDQCKMIUQJ-UHFFFAOYSA-N

物化性质

• 熔点：
  180°C

计算性质

• 辛醇/水分配系数(LogP)：
  4.0
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  62.6
• 氢给体数：
  0
• 氢受体数：
  14

安全信息

• 安全说明：
  S26,S37
• 危险类别码：
  R36/37/38
• 海关编码：
  29339900
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

制备方法与用途

用途：磷正离子型多肽缩合剂。

文献信息

• NANOMATERIALS
  申请人：Guide Therapeutics, Inc.

  公开号：US20210169804A1

  公开（公告）日：2021-06-10

  Lipid nanoparticle compositions for delivery of nucleic acids are described. The lipid nanoparticle may contain a conformationally constrained ionizable lipid as part of the composition. These compositions may allow for delivery of cargo without the need for a targeting ligand.

  描述了用于传递核酸的脂质纳米粒子组合物。脂质纳米粒子可能包含作为组合物的一部分的构象受限的可离子化脂质。这些组合物可能允许传递货物而无需靶向配体。
• TWO-PACK TYPE EPOXY RESIN COMPOSITION FOR FIBER-REINFORCED COMPOSITE MATERIAL, AND FIBER-REINFORCED COMPOSITE MATERIAL
  申请人：Toray Industries, Inc.

  公开号：EP3476877A1

  公开（公告）日：2019-05-01

  There is provided a two-pack epoxy resin composition that is excellent in viscosity stability at a low temperature (40°C) of an epoxy resin composition after mixing preparation, retains low viscosity at the time of injection into reinforcing fiber and is excellent in impregnation property, and controls resin flow by appropriate increase in the resin viscosity after the impregnation, for example, can reduce burrs on the formed product, cures in a short time at the time of formation, and gives a fiber-reinforced composite material high in transparency of a cured product and excellent in formed product quality, and a fiber-reinforced composite material made by using the same. The two-pack epoxy resin composition for a fiber-reinforced composite material of the present invention is a two-pack epoxy resin composition for a fiber-reinforced composite material containing the following components [A] to [E], in which the content of the component [A] is 5 to 45 parts by mass, the content of the component [B] is 5 to 50 parts by mass, and the content of the component [C] is 5 to 50 parts by mass, relative to 100 parts by mass of the total of the components [A], [B] and [C], and the fiber-reinforced composite material of the present invention is a fiber-reinforced composite material obtained by combining the two-pack epoxy resin composition for a fiber-reinforced composite material and a reinforcing fiber, and curing them. • component [A]: an alicyclic epoxy resin • component [B]: an aliphatic epoxy resin • component [C]: a bisphenol type epoxy resin • component [D]: an acid anhydride • component [E]: a compound selected from the group consisting of quaternary ammonium salts, quaternary phosphonium salts, and imidazolium salts.

  本发明提供了一种双组分环氧树脂组合物，该组合物在混合制备后的低温（40°C）下具有优异的粘度稳定性，在注入增强纤维时保持低粘度，并具有优异的浸渍特性，在浸渍后通过适当提高树脂粘度来控制树脂流动、例如，可减少成型产品上的毛刺，在成型时可在短时间内固化，固化产品的透明度高，成型产品的质量优异，可获得纤维增强复合材料和使用该材料制成的纤维增强复合材料。 本发明的纤维增强复合材料用双组分环氧树脂组合物是一种纤维增强复合材料用双组分环氧树脂组合物，含有以下组分[A]至[E]，其中组分[A]的含量为 5 至 45 份（按质量计），组分[B]的含量为 5 至 50 份（按质量计），组分[C]的含量为 5 至 50 份（按质量计）、相对于组分[A]、[B]和[C]总质量的 100 重量份，组分[C]的含量为 5 至 50 重量份，本发明的纤维增强复合材料是将纤维增强复合材料用双组分环氧树脂组合物和增强纤维混合并固化后得到的纤维增强复合材料。 - 组分[A]：脂环族环氧树脂 - 组分[B]：脂肪族环氧树脂 - 组分[C]：双酚型环氧树脂 - 组分[D]：酸酐 - 组分[E]：从季铵盐、季鏻盐和咪唑盐组成的组中选出的化合物。
• Spirocyclic heterocycle compounds useful as HIV integrase inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10150780B2

  公开（公告）日：2018-12-11

  The present invention relates to Spirocyclic Heterocycle Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, B, X, R1, R2, R3 and R4 are as defined herein. The present invention also relates to compositions comprising at least one Spirocyclic Heterocycle Compound, and methods of using the Spirocyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.

  本发明涉及式 (I) 的螺环杂环化合物：(I) 及其药学上可接受的盐，其中 A、B、X、R1、R2、R3 和 R4 如本文所定义。本发明还涉及包含至少一种螺环杂环化合物的组合物，以及使用螺环杂环化合物治疗或预防受试者HIV感染的方法。
• Albicidin derivatives, their use and synthesis
  申请人：TECHNISCHE UNIVERSITAET BERLIN

  公开号：US10308595B2

  公开（公告）日：2019-06-04

  Antibiotically active compounds characterized by general formula (I), wherein X1, BB, BC, BD, BE and X2 are building blocks with D1, D2, D3, D4 or D5 being linkers which include carbon, sulphur, nitrogen, phosphor and/or oxygen atoms and which are covalently connecting the moities BA and BB, BB and BC, BC and BD, BD and BE and BE and BF, respectively, and wherein in particular the building block BC comprises an amino acid derivative. The compounds for use in a method of treatment of diseases, in particular for use in a method of treatment of bacterial infections are also disclosed.

  抗生素活性化合物，其特征为通式(I)，其中X1、BB、BC、BD、BE和X2为结构单元，D1、D2、D3、D4或D5为连接体，包括碳原子、硫原子、氮原子、磷原子和/或氧原子，并分别以共价方式连接摩尔体BA和BB、BB和BC、BC和BD、BD和BE以及BE和BF，其中特别是结构单元BC包括氨基酸衍生物。还公开了用于疾病治疗方法，特别是用于细菌感染治疗方法的化合物。
• Processes for preparing pharmaceutically relevant peptides
  申请人：STEALTH BIOTHERAPEUTICS CORP

  公开号：US10633415B2

  公开（公告）日：2020-04-28

  The present technology provides methods of generating the peptides, and pharmaceutically acceptable salts of the peptides and intermediates thereof. In some embodiments, the peptide is D-Arg-2′6′-Dmt-Lys-Phe-NH2.

  本技术提供了生成多肽的方法，以及多肽及其中间体的药学上可接受的盐。在某些实施方案中，多肽是D-Arg-2′6′-Dmt-Lys-Phe-NH2。